Table 1.
Immune regression of established tumors depends on both the magnitude of immune response and tumor size at the initiation of vaccination.
|
*Initiation of Immunotherapy (Day post-challenge) |
†Tumor Volume at initiation of Immunotherapy (mm3) |
‡E7 Tetramer Response (% of CD8) |
Disease Outcome (%) |
|---|---|---|---|
| Day 7 (n=83) | 11.8+/-2.0 | 19.0+/-2.2 p = 0.01 | In Remission (69%, n = 57) p < 0.001 |
| 11.1 +/-2.3 | 9.5 +/- 2.2 | Progressing (31%, n=26) |
|
| Day 14 (n=40) | 24.9 +/- 5.8 p = 0.2 |
19.3+/-2.9 | In Remission (8%, n=3) p = 0.03 |
| 39.2 +/- 3.5 | 19.7+/-2.7 | Progressing (92%, n = 37) |
|
| Day 20 (n=40) | 26.0 +/- 14.3 p = 0.048 |
18.2+/-8.1 | In Remission (8%, n = 3) p = 0.02 |
| 137+/-15.3 | 21.6+/-2.7 | Progressing (92%, n = 37) |
|
| Day 28 (n=10) | N/A | N/A | In Remission (0%) |
| 238.9 +/- 64.0 | 31.1 +/-3.9 | Progressing (100%, n = 10) |
*
All mice received lymph node-targeted immunotherapy consisting of four injections of E7 49-57 peptide + pI:C on day 1, 4, 15 and 18 starting at indicated time intervals following C3.43 tumor challenge.
†
Maximum tumor size at the initiation of immunotherapy that completely regressed for each treatment group, day 7, 14, and 20, was 37.8, 81.3, and 112.1 mm3 respectively.
‡
Immune response was evaluated by E7 49-57 tetramer assay 10 days following the last vaccination for each group.